Search

Improving epinephrine responses in hypoglycemia unawareness with real-time continuous glucose

The objective of this study was to determine whether real-time continuous glucose monitoring (CGM) with preset alarms at specific glucose levels would prove...

Effect of short-term use of a continuous glucose monitoring system with a real-time

The objective of this study was to examine whether setting the low glucose alarm of a Guardian® REAL-Time continuous glucose monitoring system (CGMS) to 80 mg/d

Using continuous glucose monitoring to detect early dysglycaemia in children participating in the ENDIA study (Sub Protocol)

Aveni Liz Haynes Davis BA (Hons), MBBChir, MA (Cantab), PhD MBBS FRACP PhD Principal Research Fellow Co-director of Children’s Diabetes Centre

School experience studies

Besides the challenges associated with their teenage years, adolescents with Type 1 Diabetes (T1D) encounter additional challenges of having a chronic condition.

3DFAACTS-SNP: using regulatory T cell-specific epigenomics data to uncover candidate mechanisms of type 1 diabetes (T1D) risk

Genome-wide association studies (GWAS) have enabled the discovery of single nucleotide polymorphisms (SNPs) that are significantly associated with many autoimmune diseases including type 1 diabetes (T1D). However, many of the identified variants lie in non-coding regions, limiting the identification of mechanisms that contribute to autoimmune disease progression.

Management of type 2 diabetes in young adults aged 18–30 years: ADS/ADEA/APEG consensus statement

Type 2 diabetes in young adults (nominally, 18–30 years of age) is a more aggressive condition than that seen in older age, with a greater risk of major morbidity and early mortality. This first Australian consensus statement on the management of type 2 diabetes in young adults considers areas where existing type 2 diabetes guidance, directed mainly towards older adults, may not be appropriate or relevant for the young adult population.

Driving with Type 1 Diabetes: Real-World Evidence to Support Starting Glucose Level and Frequency of Monitoring During Journeys

There is limited evidence supporting the recommendation that drivers with insulin-treated diabetes need to start journeys with glucose >90 mg/dL. Glucose levels of drivers with type 1 diabetes were monitored for 3 weeks using masked continuous glucose monitoring (CGM).

Four BrightSpark Fellowships awarded to early-career researchers at The Kids

Congratulations to four outstanding early-career researchers from The Kids Research Institute Australia, who have been awarded BrightSpark Foundation fellowships and project funding for 2026.

'Artificial pancreas' helps ease diabetes burden

The Centre is currently involved in an international effort to develop revolutionary closed- loop 'artificial pancreas' technology. It is also leading a multi-centre Australian trial of these portable devices at home in young people with diabetes.

Type 1 Diabetes

A lifelong auto-immune condition that can affect anyone, but is most commonly diagnosed in childhood.